A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Hepatocellular Carcinoma

In brief

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

Key facts

Study ID
NCT03778957
Run by
AstraZeneca
People needed
724
Starts
2018-11-30
Expected to finish
2026-08-31
Last updated by the study team
2026-07-15

Who can join

Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.